Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02490943 · ClinicalTrials.gov registry record · NA
A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS
A NA study, sponsored by Brown, Theodore R., M.D., MPH.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02490943 is a NA study that has completed, run by Brown, Theodore R., M.D., MPH. The registered enrollment target is 28 participants.
The verdict
NCT02490943, a NA study, has completed, sponsored by Brown, Theodore R., M.D., MPH.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.
Interventions
- OTHER Warm Compress Before Injection
- OTHER Cold Compress After Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02490943
The ClinicalTrials.gov registry entry for NCT02490943 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown, Theodore R., M.D., MPH, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warm Compress Before Injection is the first listed.
NCT02490943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02490943 about?
NCT02490943 is a clinical study titled "A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS". Peginterferon-beta-1a (PEG) is an approved treatment for relapsing forms of MS that may cause injection related erythema. This is a randomized controlled cross-over trial of superficial hot and cold modalities to reduce injection site erythema caused by PEG.
What is the current status of trial NCT02490943?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2015-06. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT02490943?
The interventions under investigation include: Warm Compress Before Injection (OTHER), Cold Compress After Injection (OTHER).
Who is sponsoring clinical trial NCT02490943?
This trial is sponsored by Brown, Theodore R., M.D., MPH, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.